The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial

What this study found

DDS-1 improved acute lactose-challenge symptom scores compared with placebo, with the clearest benefits seen for diarrhea, abdominal cramping, vomiting, and the overall 6-hour symptom score. At week 4, active vs placebo values were diarrhea 1.34 vs 1.69 (p = 0.033), abdominal cramping 1.94 vs 2.39 (p = 0.012), vomiting 0.08 vs 0.36 (p = 0.0002), and overall 9.28 vs 10.51 (p = 0.037). The authors concluded that DDS-1 is safe and provides symptomatic relief during an acute lactose challenge. No significant differences were seen for hydrogen breath testing, Bristol Stool Scale stool form, or…

Study & population

This was a randomized, double-blind, placebo-controlled, crossover trial in adults with self-reported lactose intolerance who met eligibility after a lactose challenge.

Intervention

The active intervention was a proprietary DDS-1 strain of Lactobacillus acidophilus, delivered as an oral capsule containing not less than 10 billion (1 × 10^10) CFU per dose.

Key limitation

The analysis was limited by a small sample size and early termination, with only 22 participants completing both crossover arms and some outcomes based on 23 to 24 subjects.

View full study detailsView sourceOpen PDF